Cerebrospinal fluid proteome profile in multiple sclerosis

被引:69
作者
Lehmensiek, V.
Suessmuth, S. D.
Touscher, G.
Brettschneider, J.
Felk, S.
Gillardon, F.
Tumani, H.
机构
[1] Univ Ulm, Dept Neurol, D-89081 Ulm, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, CNS Res, D-88397 Biberach, Germany
来源
MULTIPLE SCLEROSIS | 2007年 / 13卷 / 07期
关键词
cerebrospinal fluid; clinically isolated syndrome; multiple sclerosis; proteomics; relapse-remitting; 2-D gel electrophoresis;
D O I
10.1177/1352458507076406
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cerebrospinal fluid (CSF) proteins may provide important information about the pathomechanisms present in multiple sclerosis (MS). Although diagnostic criteria for early MS are available, there is still a need for biomarkers, predicting disease subtype and progression to improve individually tailored treatment. Using the two-dimensional difference gel electrophoresis (2-D-DIGE) technology for comparative analysis, we compared CSF samples from patients with MS of the relapse-remitting type (RRMS, n = 12) and from patients with clinically isolated syndrome (CIS, n = 12) suggestive of a first demyelinating attack with neurologically normal controls. Protein spots that showed more than two-fold difference between patients and controls were selected for further analysis with MALDI-TOF mass spectrometry. Immunoblot analysis was performed to confirm the validity of individual candidate proteins. In RRMS, we identified I up-regulated and 10 down-regulated proteins. In CIS, 2 up-regulated and I I down-regulated proteins were identified. One of these proteins (Apolipoprotein All) was confirmed by immunoblot. Though the pathophysiological role of these proteins still remains to be elucidated in detail and further validation is needed, these findings may have a relevant impact on the identification of disease-specific markers. Multiple Sclerosis 2007; 13: 840-849. http://msi.sagepub.com.
引用
收藏
页码:840 / 849
页数:10
相关论文
共 48 条
[1]   Tissue plasminogen activator gene expression in multiple sclerosis brain tissue [J].
Akenami, FOT ;
Sirén, V ;
Wessman, M ;
Koskiniemi, M ;
Vaheri, A .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 165 (01) :71-76
[2]   Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases [J].
Akenami, FOT ;
Siren, V ;
Koskiniemi, M ;
Siimes, MA ;
Teravainen, H ;
Vaheri, A .
JOURNAL OF CLINICAL PATHOLOGY, 1996, 49 (07) :577-580
[3]   Plasminogen activation in multiple sclerosis and other neurological disorders [J].
Akenami, FOT ;
Koskiniemi, M ;
Vaheri, A .
FIBRINOLYSIS & PROTEOLYSIS, 2000, 14 (01) :1-14
[4]   Development of biomarkers in multiple sclerosis [J].
Bielekova, B ;
Martin, R .
BRAIN, 2004, 127 :1463-1478
[5]   Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory [J].
Calabresi, P ;
Napolitano, M ;
Centonze, D ;
Marfia, GA ;
Gubellini, P ;
Teule, MA ;
Berretta, N ;
Bernardi, G ;
Frati, L ;
Tolu, M ;
Gulino, A .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (03) :1002-1012
[6]  
Chopra B, 2002, NEUROL INDIA, V50, P41
[7]   The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution [J].
Cuzner, ML ;
Gveric, D ;
Strand, C ;
Loughlin, AJ ;
Paemen, L ;
Opdenakker, G ;
Newcombe, J .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (12) :1194-1204
[8]  
Di Bacco M, 2002, COLLEGIUM ANTROPOL, V26, P77
[9]   Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients [J].
Dumont, D ;
Noben, JP ;
Raus, J ;
Stinissen, P ;
Robben, J .
PROTEOMICS, 2004, 4 (07) :2117-2124
[10]   COMPLEMENT DEPLETION SUPPRESSES LEWIS RAT EXPERIMENTAL ALLERGIC NEURITIS [J].
FEASBY, TE ;
GILBERT, JJ ;
HAHN, AF ;
NEILSON, M .
BRAIN RESEARCH, 1987, 419 (1-2) :97-103